Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Population Aged 2 Years and Older
NCT05815264Phase 1Completed
- Sponsor
- Ab&B Bio-tech Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Apr 2021
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 23-valent pneumococcal polysaccharide vaccine in pneumonia (6 arms), sponsored by Ab&B Bio-tech Co., Ltd. Primary endpoints: Incidence of any adverse event within 30 minutes after vaccination, Incidence of abnormal indicators of blood biochemistry and blood routine at 4 days and 3 more. Started Sep 2020; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumonia
Beyond the preview
Go deeper on NCT05815264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05815264.